Here's where to invest $50,000 in the new year, according to the pros
Three Wall Street investors shared with CNBC how they'd invest $50,000 in the upcoming year.
Stay updated with breaking news from Johnson Amp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Three Wall Street investors shared with CNBC how they'd invest $50,000 in the upcoming year.
While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.
"After another difficult year, there are signs that biotech is recovering into 2024," the investment bank says, citing the prospect of interest rate cuts.
Each notched a return in the triple digits, and all still look promising heading into 2024.
Analysts predict these nine Dow stocks could potentially return more than 10% in the new year.